77 related articles for article (PubMed ID: 26431649)
1. Drug-induced skin toxicity and clinical nursing of VitK cream on colorectal cancer patients.
Li AM; Miao JH; Liu H; Ma YZ; Sun ZC
Pak J Pharm Sci; 2015 Jul; 28(4 Suppl):1499-503. PubMed ID: 26431649
[TBL] [Abstract][Full Text] [Related]
2. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
3. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
[TBL] [Abstract][Full Text] [Related]
4. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
[TBL] [Abstract][Full Text] [Related]
5. Assessment of skin-related toxicity in patients with metastatic colorectal cancer treated with cetuximab.
Pacek A; Kozioł M; Püsküllüoğlu M; Tomaszewski KA; Ochenduszko S; Zygulska AL; Krzemieniecki K
Acta Dermatovenerol Croat; 2014; 22(2):137-44. PubMed ID: 25102801
[TBL] [Abstract][Full Text] [Related]
6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
7. Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
Giuliani J; Marzola M
J Gastrointest Cancer; 2013 Jun; 44(2):241-5. PubMed ID: 23532731
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruption.
Hashimoto H; Iwasa S; Yanai T; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Namikawa K; Tsutsumida A; Yamazaki N; Yamamoto H
Jpn J Clin Oncol; 2013 Jan; 43(1):92-4. PubMed ID: 23136238
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
11. Eye complications of cetuximab therapy.
Melichar B; Nemcová I
Eur J Cancer Care (Engl); 2007 Sep; 16(5):439-43. PubMed ID: 17760931
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.
Stintzing S; Fischhaber D; Mook C; Modest DP; Giessen C; Schulz C; Haas M; Boeck S; Michl M; Stemmler J; Laubender RP; Heinemann V
Anticancer Drugs; 2013 Oct; 24(9):969-74. PubMed ID: 23863616
[TBL] [Abstract][Full Text] [Related]
14. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
Rothschild SI; Betticher D; Zenhäusern R; Anchisi S; von Moos R; Pless M; Moosmann P; Popescu RA; Calderoni A; Dressler M; Rauch D; Pederiva S; Woelky R; Papet C; Bühler V; Borner M
Cancer Chemother Pharmacol; 2019 Oct; 84(4):881-889. PubMed ID: 31444619
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K
Cameli N; Zanniello R; Mariano M; Cristaudo A
Contact Dermatitis; 2020 Mar; 82(3):189-190. PubMed ID: 31707737
[No Abstract] [Full Text] [Related]
18. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Gao F
Cancer Chemother Pharmacol; 2010 Apr; 65(5):849-61. PubMed ID: 19680654
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer.
Kajizono M; Saito M; Maeda M; Yamaji K; Fujiwara S; Kawasaki Y; Matsunaga H; Sendo T
Int J Clin Oncol; 2013 Aug; 18(4):684-8. PubMed ID: 22678464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
